- Investing Ideas
- Belgian Pharmaceuticals & Biotech Healthy potentially undervalued
Belgian Pharmaceuticals & Biotech Healthy potentially undervalued
Results
2
0 new
Companies which are potentially undervalued and in an acceptable financial position.
2 companies
UCB
Market Cap: €47.1b
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
UCB
€253.90
7D
0%
1Y
51.6%
argenx
Market Cap: €36.2b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€601.20
7D
0.2%
1Y
10.2%